Munguva pfupi yapfuura, murwere ane kenza yepancreas yakaramba ichikura uyo akanga atadza kurapwa kakawanda, akaonda bundu mushure mekugamuchira KD-496 CAR-T cell therapy, uye kudzorerwa kwakasimbiswa kwakaramba kuripo mushure memazuva 180 mushure mekurapwa.
Parizvino, kuchine miedzo yakawanda yekiriniki yehunyanzvi hutsva hwekurwisa gomarara muChina huri kutsvaga varwere. Kana muchida kubvunzana nezvemishonga mitsva netekinoroji, munogona kubata Dhipatimendi reBeijing South Region Oncology Hospital International.
Nhamba yefoni: 4008803716
Nhamba yeWeChat: 17801183037
Imeyili：myimmnet@163.com
Murwere uyu, mukadzi ane makore 73 ekuberekwa, akaonekwa muna Chikunguru 2021 aine dumbu guru repancreas pamwe nekuvharika kwemukoto wenyongo. Akavhiyiwa duodenectomy, apo dumbu guru rakaenzana ne3 cm rakaonekwa pakubuda kwedumbu repancreas. Kuongororwa kwezvirwere kwakaratidza kuti adenocarcinoma yakanga yakasiyana zvishoma. Mushure mekuvhiyiwa, akapihwa albumin-bound paclitaxel (nab-paclitaxel) pamwe chete neS-1 chemotherapy, zvichiteverwa neM108 + nab-paclitaxel + gemcitabine uye LM108 pamwe chete netoripalimab. Aiva nenhoroondo yeschizophrenia nechirwere cheshuga, zvese zvichirapwa zvakanaka nemishonga.
Muna Kukadzi 2025, murwere akapihwa KD-496 CAR-T cells. Pakuongororwa kwekutanga kwebundu mavhiki mana gare gare, pasinei nekukwegura kwake uye mutoro webundu wakakwira (baseline target lesion ye58 mm), bundu raida kurongerwa rakanga radzikira ne34.5% kubva pakutanga. Pakazosvika zuva rechi60, bundu raida kurongerwa rakanga radzikira ne37.9%, uye pamazuva e90 ne180, bundu rakaramba richidzikira ne44.8%, richiramba riine chikamu chemhinduro (PR) pasina chepfu yemudumbu kana yetsinga.
Murwere ane makore makumi manomwe ekuberekwa ane kenza yemudumbu akavhiyiwa muna Kukadzi 2023, chirwere chemudumbu mushure mekuvhiyiwa chakaratidza adenocarcinoma ine maronda ari pakati nepakati kusvika asina kusiyanisa zvakanaka iyo yakanga yatopararira kuma lymph nodes, peritoneum, uye mapapu ese, pamwe chete ne ascites uye pleural effusion (chirwere chakafambira mberi, chakapararira zvakanyanya). Mavhiki masere mushure mekuvhiyiwa, akapihwa SOX chemotherapy (oxaliplatin + S-1), asi mamiriro ake akaenderera mberi. Kuedza kwakatevera nePX (paclitaxel) + PD-1 (immunotherapy) kwema cycle mana, kuteverwa ne capecitabine + nivolumab, kwakakundikanawo kumisa kufambira mberi. Pakupedzisira, nivolumab + fruquintinib (mushonga unorwisa angiogenic) yakapihwa, asi isina kushanda zvakanaka.
Pazuva rechi28 rekurapwa kweCAR-T, bundu rakanga radzikira ne47.3% zvichienzaniswa nerapi isati yatanga, zvichiita kuti pave nemhinduro yakadzika (PR). Pazuva rechi60, bundu rakaramba richidzikira ne41.9%, richiramba riine PR yakasimbiswa, zvichiratidza kurapwa kwakasimba uye kunoshanda.
Murwere ane makore makumi mashanu nemashanu ekuberekwa ane kenza yemudumbu akavhiyiwa laparoscopic radical gastrectomy muna Mbudzi 2023, chirwere chemushure mekuvhiyiwa chikaratidza kusasiyana zvakanaka kweadenocarcinoma ine chikamu che signet-ring cell carcinoma (ine kenza yakanyanya kuipa). Akaedza mishonga yakawanda ye chemotherapy + immunotherapy, kusanganisira oxaliplatin + capecitabine + sintilimab, oxaliplatin + leucovorin + sintilimab, nab-paclitaxel + sintilimab + fruquintinib, uye irinotecan monotherapy. Zvisinei, muna Kukadzi 2025, chirwere chake chakakurumidza kukura, zvikaita kuti kurapwa kwakajairika kusashande.
Akabva apihwa CAR-T cell therapy, uye pazuva rechi28, bundu rakanga radzikira ne31.8% zvichienzaniswa nerapi isati yatanga, zvichiita kuti pave nechikamu chemhinduro (PR), uye kudzora chirwere kwakabudirira.
Parizvino, kuchine miedzo yakawanda yekiriniki yehunyanzvi hutsva hwekurwisa gomarara muChina huri kutsvaga varwere. Kana muchida kubvunzana nezvemishonga mitsva netekinoroji, munogona kubata Dhipatimendi reBeijing South Region Oncology Hospital International.
Nhamba yefoni: 4008803716
Nhamba yeWeChat: 17801183037
Imeyili：myimmnet@163.com
Nguva yekutumira: Chikunguru-31-2025